All relevant data are within the manuscript and its Supporting Information files.

Introduction {#sec001}
============

The hub of the mechanism that drives bacterial mitosis, or partition, is a complex formed by binding of a specific ParB protein to a small number of clustered *parS* binding sites. The *parS* array functions as a centromere, and the complex serves as a kinetochore by activating the corresponding ParA ATPase to segregate replicas of its own chromosome or plasmid to incipient daughter cells. ParBs of most low copy-number plasmids and of all known chromosomes bind to their cognate *parS* sites as dimers, primarily via a helix-turn-helix (HTH) motif. They also bind, more weakly, to non-specific DNA. But unlike other proteins that bind through HTH motifs, notably transcription regulators, ParB proteins self-associate (oligomerize) and so pervade nearby DNA to enlarge their complex, a process termed \"spreading\". Spreading is not only integral to the partition process but has also enabled use of ParB/S systems as an alternative to fluorescent repressor-operator systems (FROS) for visualization of genetic loci in bacteria \[[@pone.0226472.ref001],[@pone.0226472.ref002]\]. We have developed them for use in eucaryote cells and viruses as the ANCHOR system \[[@pone.0226472.ref003]--[@pone.0226472.ref005]\]. They offer certain advantages over FROS: the weakness of ParB oligomerization and DNA binding interactions allows other chromatin-based processes to disperse the complexes easily, making them less disruptive than FROS, and the small number of integrated *parS* binding sites involved is less locally intrusive than the hundreds typical of FROS. Nevertheless, dispensing with the need for prior *parS* integration through direct binding to endogenous sequences would eliminate potential artifacts of even such minor genome modification and would greatly streamline the procedure. Fusion of the ParB and fluorescent peptide (FP) components to proteins whose binding can be tailored to recognize natural genome sequences---TALE and Cas9---might allow specific tagging of unaltered sites while preserving the advantages of ParB/S systems. However, this would work only if ParBs can spread without first binding to their *parS* sites. It was not clear that they can. To assess the feasibility of removing the *parS* integration step from the ANCHOR system we have aimed in the work reported here to identify the interactions that enable ParB spreading.

HTH-type ParB proteins share a broadly consistent three-domain organization of both structure and function. The intrinsically disordered N-terminal domain interacts with ParA \[[@pone.0226472.ref006]\] and with itself \[[@pone.0226472.ref007]\], the central domain contains the motifs responsible for specific *parS* recognition and for DNA binding \[[@pone.0226472.ref008]--[@pone.0226472.ref012]\], and the C-terminal domain dimerizes the protein \[[@pone.0226472.ref006],[@pone.0226472.ref007],[@pone.0226472.ref009],[@pone.0226472.ref013]\] to form the basic active ParB unit; in certain ParBs the latter also plays roles in DNA binding and ParA interaction \[[@pone.0226472.ref014]--[@pone.0226472.ref016]\].

Early studies of mutant ParBs of the P1 and F plasmids implicated the N-terminal domain of these proteins in spreading \[[@pone.0226472.ref008],[@pone.0226472.ref017]--[@pone.0226472.ref019]\], as also confirmed later for chromosomal ParBs \[[@pone.0226472.ref014],[@pone.0226472.ref020]\], and suggested that spreading is needed for partition. These observations, together with the demonstration that the N-terminal domain oligomerizes P1 ParB dimers \[[@pone.0226472.ref007]\], the known binding of HTH proteins to non-specific DNA and the small number of foci seen in cells containing fluorescent ParB derivatives \[[@pone.0226472.ref021],[@pone.0226472.ref022]\] led to the general view that ParB bound in the core complex recruits further ParB molecules whose weak interactions with themselves and with neighbouring non-specific DNA create a metastable complex large and cohesive enough to activate partition \[[@pone.0226472.ref023]\]. Spreading was initially envisaged as proceeding laterally from the centromere along adjacent DNA. However, certain observations were inconsistent with this view \[[@pone.0226472.ref024],[@pone.0226472.ref025]\], and Bouet *et al*. \[[@pone.0226472.ref026]\] proposed that ParB spreads not only *in cis* from the nucleating complex but also *in trans* to the nucleoid and to distant sites on the same molecule, like bees round a hive rather than birds on a wire. The transient bridging (*trans*) and looping (*cis*) interactions and the indeterminate form of the complex implied by this proposal have since been substantiated and refined by studies of complexes formed by the ParB proteins of several species \[[@pone.0226472.ref027]--[@pone.0226472.ref031]\], and the idea has recently been extended to the chromatin realm \[[@pone.0226472.ref032]\].

However, the full role of centromere binding in formation of higher-order partition complexes is not yet understood. Since spreading is not seen to occur spontaneously, in the absence of *parS*, it would appear to need a specific switch in ParB conformation. Is this induced directly upon binding to *parS*? Or is it a consequence of the oligomerization interaction of ParB N-terminal domains, with *parS* binding serving only to focus and anchor the complex? ([Fig 1](#pone.0226472.g001){ref-type="fig"}) On one hand there are indications that the properties of ParBs do change in response to centromere binding: F SopB and P1 ParB co-repressor activity is stimulated *in trans* by *sopC* and *parS* respectively \[[@pone.0226472.ref033],[@pone.0226472.ref034]\], SopB-mediated stimulation of SopA ATP hydrolysis is enhanced by *sopC* \[[@pone.0226472.ref035]\] and a newly-discovered CTPase activity exhibited by some ParB proteins, including SopB, is enhanced by centromere binding \[[@pone.0226472.ref036],[@pone.0226472.ref037]\]. On the other hand, Surtees & Funnell \[[@pone.0226472.ref007]\] observed oligomerization of P1 ParB N-terminal domains in the absence of *parS in vitro* and in yeast, and Hyde *et al*. \[[@pone.0226472.ref038]\] concluded that specific binding of KorB did not reduce intrinsic disorder but rather selected from a population of natural conformers.

![ParB activation mechanisms.\
Possible mechanisms responsible for a conformation change in ParB dimers that enables them to enlarge the partition complex through oligomerization, i.e. to spread. Several, non-exclusive, activation mechanisms can be envisaged, it being assumed that the active conformation is maintained for a significant fraction of the partition complex lifetime. Dimers able to spread are shown in red, those unable to in grey. The activating conformational change is depicted by blue arrows. **A.** mechanisms independent of the centromere: **(i)** ParB dimers are intrinsically capable of oligmerization and need no specific activation. **(ii)** Two forms of ParB, able and unable to oligomerize, are interconvertible via a spontaneous conformational shift. **(iii)** An initial dimer-dimer interaction induces the activation that allows the dimers to then participate independently in spreading. **B.** mechanisms requiring the centromere: **(i)** Centromere-bound dimers activated by binding or withdrawn from a pool in conformer equilibrium, as in Aii, interacts selectively with other active dimers, thus trapping them near the centromere and shifting the diffusible ParB equilibrium towards the active form. **(ii)** Inactive dimers are activated through contact with already active dimers residing on the centromere (or with previously released activated dimers). **(iii)** Successive binding of inactive dimers, activation by the centromere and release builds a pool of active dimers. **C.** Loss of the conformation enabling oligomerization could return dimers to the inactive pool for recycling.](pone.0226472.g001){#pone.0226472.g001}

We report here our attempts to observe spreading of ParBs fused to non-*parS* DNA-binding proteins, and to distinguish ParB-*parS* binding from ParB-ParB interaction as the basis for conversion to spreading competence.

Materials and methods {#sec002}
=====================

Strains {#sec003}
-------

### Bacteria {#sec004}

*E*.*coli* K12 strains used in microscopy and gene expression experiments were derivatives of W1485, as detailed in [Table 1](#pone.0226472.t001){ref-type="table"} and schematized in [S1 Fig](#pone.0226472.s001){ref-type="supplementary-material"}. Transformation recipients were DH5α and DH10B \[[@pone.0226472.ref039]\] except for constructions involving recombination-prone RVD repeats of *tal* genes where SURE2 (Stratagene) or a derivative cured of the F\', D111, was used. The host for recombinational transfer of centromere sequences from plasmids to λ phages \[[@pone.0226472.ref040]\] was MC1061 \[[@pone.0226472.ref041]\].

10.1371/journal.pone.0226472.t001

###### Bacterial strains.

![](pone.0226472.t001){#pone.0226472.t001g}

  Strain    Genotype/relevant properties                                                                                                                   Source
  --------- ---------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------
  CB0129    *thi*, *leu*, *thyA*, *deoB*, *supE*                                                                                                           \[[@pone.0226472.ref042]\]
  DLT812    CB0129 Δ(*ara-leu*)*7696*, *zac3051*::Tn*10*                                                                                                   \[[@pone.0226472.ref043]\]
  DLT1215   DLT812 *rpsL812*                                                                                                                               \[[@pone.0226472.ref044]\]
  DLT1912   DLT812 Ω*Pcp*18::*araE*533, by P1-transduction with *frt*.*kan*.*frt* and Flp-excision of *frt-kan*                                            this work
  DLT2067   MC1061 Ω*Pcp*18::*araE*533, Δ*ara*(*FGH*), λRS45-*sopC*-*rpsL*^+^-*cat*                                                                        \[[@pone.0226472.ref044]\]
  DLT2074   DLT1215 *xylE*::*sopC*                                                                                                                         \[[@pone.0226472.ref031]\]
  D135      DLT1912 Δ*ara*(*FGH*), by P1 transduction with *frt*.*cat*.*frt* and Flp-excision of *frt*.*cat*                                               this work
  D143      D135 λRS88-*frt*.*aadA*.*frt*-4xIR-p*cry*::*lacZ* lysogen, transfer from pDAG545                                                               this work
  D150      D135 λRS45-*sopC*-*rpsL*^+^-*cat* lysogen, transduction from DLT2067                                                                           this work
  D179      D135 Δ*lacZ4787*, Δ*lacA*, by transduction with *frt*.*kan*.*frt* from JW0333 (Keio collection) and Flp-excision of *frt*.*kan*                this work
  D183      D143 Δ*lacZ4787*, Δ*lacA* by transduction with *frt*.*kan*.*frt* from JW0333 (Keio collection) and Flp-excision of *frt*.*kan*, *frt*.*aadA*   this work
  D195      D179 λRS88-*sopC-pldc* lysogen, transfer from pDAG418                                                                                          this work

### Yeast {#sec005}

The progenitor of the *Saccharomyces cerevisiae* strains ([Table 2](#pone.0226472.t002){ref-type="table"}) was strain W303, a gift from Frederic Beckouet. It was sequentially modified by (i) Cas9-mediated insertion of a Gal:HO cassette at ade3---W303 cells were transformed by ade3::Gal:HO DNA with the plasmids p414-TEF1p-Cas9-CYC1t and pRPR1-gRNA.ADE3-RPR1t, (ii) deletion of the *ho* gene by insertion and excision of a URA3 cassette, and (iii) lithium acetate transformation with a cassette of URA3 flanked by sequences at Chr3:197kb, yielding ySA46. ySA27 was obtained by substituting the URA3 cassette of ySA46 for a ANCH3 cassette, with 5-fluoroorotic acid selection for ura^**-**^.

10.1371/journal.pone.0226472.t002

###### Yeast strains.

![](pone.0226472.t002){#pone.0226472.t002g}

  Strain   Genotype/relevant properties                         Source
  -------- ---------------------------------------------------- -------------
  W303     leu2-3,112 trp1-1 can1-100 ura3-1ade2-1 his3-11,15   F. Beckouet
  ySA27    W303 Δho ade3::Gal-HO Anch3\@chIII.197kb             this work
  ySA46    W303 Δho ade3::Gal-HO URA3\@chIII.197kb              this work

Plasmid constructions {#sec006}
---------------------

Construction outlines are given here; details are available on request. Relevant characteristics of plasmids are given in [Table 3](#pone.0226472.t003){ref-type="table"}.

10.1371/journal.pone.0226472.t003

###### Plasmids.

![](pone.0226472.t003){#pone.0226472.t003g}

  Name      Relevant characteristics                                                                           Source (this work, except as noted)
  --------- -------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------
  pGB2      *ori-rep*~**pSC**~, *aadA*                                                                         \[[@pone.0226472.ref050]\]
  pDAG123   *ori*~**pBR**~, p*ldc-lacZYA*, *kan*, *bla*                                                        \[[@pone.0226472.ref043]\]
  pDAG170   *ori*~**pBR**~, *araC*-p*araBAD*-*sopA\'sopB*~**F**~, *cat*                                        \[[@pone.0226472.ref026]\]
  pNR120    *ori-rep*~**pSC**~\*, p*LtetO-sopA*^**N15**^-*sopB*^**N15/F**^, *cat*                              \[[@pone.0226472.ref009]\]
  pRS415    *ori*~**pBR**~, *bla*, *lacZYA*; promoter assay vector                                             \[[@pone.0226472.ref040]\]
  pZS\*21   *ori-rep*~**pSC**~\*, p*LtetO*, *kan*                                                              \[[@pone.0226472.ref051]\]
  pCAT02    *ori*~p15A~, po*tetA -dCas9*, *aadA*                                                               
  pCAT05    *ori*~p15A~, po*tetA -sopB*^**R219A**^::*dCas9*, *cat*                                             
  pCAT06    *ori*~pUC~, p*J23119-sgRNA*^**0**^, *bla*                                                          
  pCAT08    *ori*~pUC~, p*J23119-sgRNA*^**sopC**^, *bla*                                                       
  pCAT10    *ori*~pSC~, p*lac-sopB*^**R219A**^::mVenus, *aadA*                                                 
  pCAT13    *ori*~p15A~, po*tetA -Cas9*, *aadA*                                                                
  pCAT15    *ori*~p15A~, po*tetA -sopB*^**+**^::*dCas9*, *cat*                                                 
  pCAT168   *ori*~pUC~, p*J23119-sgRNA*^**MS2**^, *bla*                                                        
  pCAT180   *ori*~pUC~, p*J23119-sgRNA*^**sopC2**^, *bla*                                                      
  pCAT184   *ori*~pUC~, p*J23119-sgRNA*^**xylE**^, *bla*                                                       
  pJYB294   *ori*~pSC~, p*lac-sopB*^**+**^::mVenus, *aadA*                                                     \[[@pone.0226472.ref031]\]
  pSA312    *ori*~**2μ**~, ori~**pBR**~, p*Cyc1*-*or3*::*mCh*, *trp1*                                          
  pSA316    *cen6-ars4*, ori~**pBR**~, p*Tef*α-*or3*::*tal*.*U3aL*, *leu2*                                     
  pNR129    *ori-rep*~**pSC**~\*, p*LtetO-sopA*^**N15**^Δ(cdns 4--248)-*sopB*^**N15/F**^::*megfp*, *kan*       
  pNR195    miniP1 (*ori-repA-parABS*), p*ara*, *cat*                                                          
  pNR197    miniP1 (*ori-repA-parABS*), p*ara*-*sopA*^**N15**^Δ(4--248)-*sopB*^**N15**^::*megfp*, *cat*        
  pNR189    miniP1 (*ori-repA-parABS*), p*ara-sopA*^**N15**^Δ(4--248)-*sopB*~**N15**~, *cat*                   
  pNR198    miniP1 (*ori-repA-parABS*), p*LtetO-sopA*^**N15**^Δ(40--355)-*sopB*~**F.R219A**~::*megfp*, *bla*   
  pDAG418   *ori*~**pBR**~, *sopC*                                                                             
  pDAG525   miniP1 (*ori-repA-parABS*), p*LtetO-sopA*^**N15**^Δ(40--355)-*sopB*~**F**~::*megfp*, *cat*         
  pDAG541   pRS415 4xIR-p*cry*::*lacZ*                                                                         
  pDAG545   pDAG541 *frt-aadA-frt*                                                                             
  pDAG607   *ori-rep*~**pSC**~, p*ara-sopA*^**N15**^Δ(40--355)-*sopB*~**F**~, *aadA*                           rep~pSC~\* is a low copy-number mutant of pSC101 isolated by Xia *et al*. \[[@pone.0226472.ref052]\]

### ANCHOR system visualization {#sec007}

Tale constructs were based on the pZHY501 shuttle (*S*.*cerevisiae-E*.*coli*) vector, provided by Daniel Voytas (via Addgene) \[[@pone.0226472.ref045]\], which carries the Nt and Ct (non-RVD) domains of the *X*.*oryzae* Tale PthXo1 gene fused to the FokI nuclease coding sequence. pZHY501was modified by site-specific mutagenesis to introduce sites for *Avr*II and *Nru*I immediately upstream of the Tale *Nt* sequence, and by deletion of the *fokI* gene using *Bam*HI, *Bsa*BI and Klenow polymerase, yielding pVR203. Repeat variable di-residue (RVD) domains specific for URA3 Nter nt 17--32 (U3aL) and Cter nt 632--648 (U3bR) were obtained as *Bsm*BI site-ended PCR products from plasmids kindly provided by Bing Yang \[[@pone.0226472.ref046]\], and inserted between the *Bsm*BI sites in pVR203 to create the *Nt*::*ura3*::*Ct* fusions in pVR204 (U3aL) and pVR206 (U3bR). A codon-optimized synthetic *or3* (*parB*) gene \[[@pone.0226472.ref004]\] was obtained as a PCR product with terminal *Avr*II and *Nru*I sites and inserted between these sites in pVR204 to create the *or3s*::*tal*.U3aL fusion in pSA316. The stop\>leu-mutated codon of the same *or3s* gene was fused to codon 2 of the mCherry coding sequence; the *or3s*::*mCh* fusion was inserted into a vector then excised with *Kpn*I and *Not*I and inserted between these sites of pRS424 \[[@pone.0226472.ref047]\], yielding pSA312.

### SopB::mVenus visualization {#sec008}

Plasmids producing SopB::mVenus were pCAT10, made by joining *ori*^**pSC101**^-p*lac*, *cat* and *sopB*^**R219A**^::*mVenus* PCR fragments, and pJYB294, the *sopB*^**+**^, *aadA* equivalent. Plasmids producing SopB::dCas9 were derived from the p15A-based plasmid pdCas9 (\[[@pone.0226472.ref048]\]; Addgene \#44249): substitution of *aadA* (Sp^R^) for *cat* gave pCAT02, insertion of *sopB*^**R219A**^ and linker (ELGSG)-*dCas9* 5'-terminus PCR fragments into pCAT02 gave pCAT05, and an equivalent insertion of *sopB*^+^ into pdCas9 gave pCAT15. Plasmids producing sgRNAs were derived from pgRNA (Addgene \#44251): deletion of the promoter-gRNA interval by inverse PCR gave pCAT06, while replacement of this interval by a 20bp sequence from *sopC* (one arm of the palindrome and its flank, to avoid hairpin formation), *xylE* and an unrelated MS2 sequence ("random") gave pCAT08, -184 and -168 respectively. *AadA* was substituted for *cat* in pwtCas9 (Addgene \#44250) to give pCAT13.

SopB::mEgfp visualization {#sec009}
-------------------------

Plasmids carrying the hybrid *sopB* (N15 codons 1--175: F codons 174--323) transcribed from the p*L-tetO* promoter were derived from pNR120 by in-frame deletion of *sopA* residues 4--248 (pNR123), replacement of *cat* by *kan* (pNR127) and fusion of *sopB*^**N15/F**^ 5\' to *megfp*, yielding the signalling plasmid pNR129.

Plasmids carrying *sopB*^**N15**^ were derived from pZC326 \[[@pone.0226472.ref044]\], a mini-F---mini-P1 hybrid into which we inserted a high copy-number origin, making pDAG382, to facilitate construction. To place *sopB*^**N15**^ under *araC-paraBAD* control we substituted it for *sopB*^**F**^ in pDAG170 \[[@pone.0226472.ref026]\]. The *araC-para-sopA\'-sopB*^**N15**^ expression unit was joined to the mini-P1 portion of pZC326 to make the binding plasmid pNR189, and *sopA\'-sopB*^**N15**^ deleted from pNR189 to make the control plasmid pNR195. The *megf* gene (see below) was amplified by PCR and fused to the *sopB*^**N15**^ 3\' end in pNR189 to make pNR197.

Plasmids carrying *sopB*^**F**^ were constructed as follows. pDAG607: transfer of the *araC-para-sopA\'-sopB*^**F**^ unit from pDAG170 to pGB2. pDAG525: fusion of *sopA\'-sopB*^**F**^ to *egfp* downstream of p*LtetO* in a pZS21\* vector, followed by successive replacements of *egfp* by *megfp*, *kan* by *cat*, and the vector by the mini-P1 segment of pZC326. pNR198: replacement of *sopB*^**+**^ in pDAG433 \[[@pone.0226472.ref009]\] by *sopB*^**F.R219A**^ amplified from pJYB223 \[[@pone.0226472.ref012]\], in-phase insertion of *megfp* 3\' to the *sopB*^**F.R219A**^, and joining of the p*LtetO-sopA\'-sopB*^**F.R219A**^::*megfp-bla* segment to the mini-P1 portion of pZC326.

Plasmids for centromere transfer to attλ: the *sopC* sequence was inserted between the *kan* gene and the p*ldc* promoter in pDAG123 \[[@pone.0226472.ref043]\] to give pDAG418. A *frt-aadA-frt* cassette was inserted upstream of the 4xIR unit (see below) in pDAG541 to give pDAG545.

### 4xIR construction {#sec010}

To make an N15 centromere comparable to *sopC* of F, we joined the four IR sites to each other such that the centres of adjacent IRs are separated by 43bp. Four pairs of complementary oligonucleotides, corresponding to each of the natural IRs and its flanks ([Table 4](#pone.0226472.t004){ref-type="table"}), were designed to form duplexes with 5\' extensions permitting ligation in a defined order. All oligonucleotides except f1t and f4b were phosphorylated with T4 polynucleotide kinase, annealed pairwise by heating and slow cooling, then mixed and incubated with T4 DNA ligase. Ligation products were amplified by PCR using f1t and f4b as primers, and the PCR products digested with *Apa*LI, *Hin*dIII and *Bsr*GI to remove self-ligated products, size-selected by gel electrophoresis, phosphorylated, and ligated with *Sma*I-digested, dephosphorylated pRS415, yielding pDAG541.

10.1371/journal.pone.0226472.t004

###### Oligonucleotides for N15 "centromere".

![](pone.0226472.t004){#pone.0226472.t004g}

  --------------------------------------------------------------------------------------------
  f1t    5\'-AATTCTTCTTCCGGCT**GTGCGACC**$\mathbf{AC}$**GGTCGCAC**CATTCCGTTGG
  f1b            GAAGAAGGCCGA**CACGCTGG**$\mathbf{TG}$**CCAGCGTG**GTAAGGCAACCACGT-\'5    IR1
  f2t        TGCAGTCAAAGAGG**GTGCGACC**$\mathbf{TC}$**GGTCGCAC**GAGATAATGAA
  f2b              CAGTTTCTCC**CACGCTGG**$\mathbf{AG}$**CCAGCGTG**GAGATAATGAATCGA-\'5    IR2
  f3t        AGCTGTCTGATATC**GTGCGACC**$\mathbf{AT}$**GGTCGCAC**GGAATAGAAAT
  f3b              CAGACTATAG**CACGCTGG**$\mathbf{TA}$**CCAGCGTG**CCTTATCTTTACATG-\'5    IR3
  f4t        GTACGTCCGCTTTC**GTGCGACC**$\mathbf{AC}$**GGTCGCAC**GCTTTTCCATTCT
  f4b              CAGGCGAAAG**CACGCTGG**$\mathbf{TG}$**CCAGCGTG**CGAAAAGGTAAGACTAG-\'5  IR4
  --------------------------------------------------------------------------------------------

### Monomer Egfp mutant {#sec011}

To impede the tendency of the original Egfp (Clontech) to dimerize we introduced the A206K mutation by strand-overlap extension PCR \[[@pone.0226472.ref049]\] using mutagenic primers A206K.H3-3 and A206K.H3-4 and flanking primers SopBN15.949--972 and Xba-dsegfp. The *egfp*^**A206K**^ product was initially fused to *sopB*^**N15**^ (pSA579), then to *sopB*^**F**^ with an *Xho*I site between the *sopB* and *egfp* genes (pDAG524), and finally to *sopB*^**N15/F**^ (pNR129). Primers (mutagenic bases underlined):

10.1371/journal.pone.0226472.t005

![](pone.0226472.t005){#pone.0226472.t005g}

  ------------------ ------------------------------------------------
  A206K.H3-3         CCCAGTCC[AAG]{.ul}CT[T]{.ul}AGCAAAGACCCCAACG
  A206K.H3-4         CTTTGCT[A]{.ul}AG[CTT]{.ul}GGACTGGGTGCTCAGGTAG
  SopBN15.949--972   GCAGAATTAGGTGCAGCTGAGCAG
  Xba-dsegfp         GAATTCTAGAGTCGCGGCCGCTTTACTTG
  ------------------ ------------------------------------------------

Media and growth conditions {#sec012}
---------------------------

### Bacteria {#sec013}

Routine cultures were grown with aeration at 37°C in Luria-Bertani broth supplemented as appropriate with (μg/mL) kanamycin (15), chloramphenicol (10), and spectinomycin (20), or at twice these concentrations for solid (1.5% agar) media, and with ampicillin (100) and tetracycline (10) for both.

Cultures for gene expression and microscopy were grown with aeration at 30°C in M9 salts supplemented with thymine (20μg/mL), Casamino acids (0.2%), thiamine (1μg/mL), 0.2% glucose or glycerol (MGC and MglyC respectively), antibiotics as above and inducers IPTG, anhydrotetracycline (aTc) and arabinose as needed (see legends).

### Yeast {#sec014}

The basic medium was SC: 0.67% yeast nitrogen base (Difco) supplemented with all amino-acids except those used for selection, uracil, adenine and 2% glucose.Strains W303, ySA27 and ySA46 transformed with pSA312 alone or with pSA312 and pSA316 were grown overnight in SC lacking leucine (SC-LEU) or leucine and tryptophan (SC-LEU-TRP) respectively.

### DNA manipulation {#sec015}

*In vitro* manipulation and construction of plasmids employed standard materials and procedures. DNA polymerases in PCR were Phusion (New England Biolabs) for synthesis of DNA used in constructions and DreamTaq (Thermo Fisher) for routine screening.

### SopB::Cas9 killing assay {#sec016}

Binding of dCas9 to the site targeted by the sgRNAs used in this study was verified by testing the ability of wtCas9 at low concentration to cleave target DNA. The test strain DTL2074 was co-transformed by the compatible plasmid pairs to be tested, one expressing the sgRNA, the other wtCas9 (pCAT2) or dCas9 (pCAT13). Transformed bacteria were grown without anhydrotetracycline on plates selective for both plasmids (with Sp and Ap) for 24 hours at 37°C. Specific Cas9 binding to the targeted site was determined by the absence of colony growth in the presence of wtCas9 but not of dCas9.

Microscopy {#sec017}
----------

### Bacteria {#sec018}

Colonies of strains freshly transformed with plasmids carrying the *sopB* genes to be tested were used to inoculate MGC or MglyC at a concentration permitting at least 10 generations of exponential growth (doubling times of \~60 and \~120 minutes respectively), and incubated at 30°C to an optical density at 600nm of 0.1--0.2 for viewing mEgfp fluorescence or 0.3--0.4 for mVenus. Samples were applied as 0.7μL drops to the surface of a layer of 1% agarose in growth medium, as described \[[@pone.0226472.ref053]\]. The cells were viewed at 30°C using an Eclipse TI‐E/B wide field epifluorescence microscope with a phase contrast objective (CFI Plan APO LBDA 100X oil NA1.45) and a Semrock filter YFP (Ex: 500BP24; DM: 520; Em: 542BP27) or FITC (Ex: 482BP35; DM: 506; Em: 536BP40). Images were taken using an Andor Neo SCC-02124 camera with illumination at 80% from a SpectraX source Led (Lumencor) and exposure times of 0.5-1second. Nis‐Elements AR software (Nikon) was used for image capture and editing.

### Yeast {#sec019}

Live-cell microscopy was performed as described \[[@pone.0226472.ref054]\], using an Olympus IX-81 wide-field fluorescence microscope equipped with a CoolSNAPHQ camera (Roper Scientific) and a Polychrome V (Till Photon-ics) electric piezo accurate to 10 nm, and an Olympus oil immersion objective 100X PLANAPO NA1.4. Yeast cells were spread on a layer of SD-agarose (YNB + 2% dextrose + 2%(w/v) agarose) set in a microscope slide trough. mCherry signal was acquired in 3D as 21 focal planes at 0.2 μm intervals with an acquisition time of 300ms.

### Silencing assay {#sec020}

Transcription reporter strains freshly transformed with plasmids carrying the *sopB* genes to be tested were grown as for microscopy (above) at 30°C to an optical density of 0.1--0.2 and chilled on ice. Samples were removed for assay of β-galactosidase and measurement of optical density as described \[[@pone.0226472.ref055]\].

### Western blotting {#sec021}

Cells from exponentially-growing bacterial cultures were resuspended in SDS-loading buffer (10% glycerol, 5% β-mercaptoethanol, 2.3% SDS, 62.5mM Tris-HCl pH 6.8, 0.25% bromophenol blue), heated at 95°C for 5 minutes with occasional vortexing, and centrifuged. Samples corresponding to 0.033 OD~600~ units were subjected to PAGE on 4--12% gradient gels run at 200V for 50 minutes in either MOPS or Tris-glycine buffer. Proteins were transferred semi-dry to PVDF (0.2μm) membranes using a Transblot Turbo apparatus (Biorad), then exposed successively, with intermediate washing, to Tween-milk blocking buffer, rabbit α-SopB (1:1000; Eurogenetec), goat anti-rabbit IgG coupled to Horse-radish peroxidase (1:1000) and ECL reagent (Clarity Western) before scanning (Gel Doc). Exponential phase yeast cells were concentrated and broken with glass beads using a Beads Beater. After centrifugation to remove debris, protein concentrations of the supernatants were measured with Bradford reagent and 20μg of each heated in loading buffer and subjected to PAGE on Biorad 4--15% gradient gels in Tris-glycine. Transfer and immunodetection were as in A, except that anti-GFP was used.

Results {#sec022}
=======

We begin by describing two of our attempts to observe partition complex assembly primed by specific binding to DNA sites other than the ParB protein\'s own centromere. One employs a plasmid site inserted in the *E*.*coli xylE* gene, the other involves several sites, natural and exogenous, within *S*.*cerevisiae* chromosomes.

E.coli xylE {#sec023}
-----------

The CRISPR-Cas9 system was used. A guide RNA with a 20 nt sequence of *xylE* (sgRNA-*xylE*) was co-produced with a polypeptide comprising the F plasmid SopB protein fused at its C-terminus to the enzymatically inactive dCas9 protein. The ability of this fusion to recognise its target was confirmed by the lethality of the SopB fusion to active Cas9 both in *xylE* ^+^ cells producing sgRNA-*xylE* and in cells with an insertion of the F *sopC* centromere producing sgRNA-*sopC* ([S1 Table](#pone.0226472.s005){ref-type="supplementary-material"}). Western blot analysis confirmed production of adequate quantities of the dCas9 fusion proteins; despite variability in immunostaining signal, we could estimate that the SopB-fusion proteins were present at a minimum of 300 monomers per cell ([S2A Fig](#pone.0226472.s002){ref-type="supplementary-material"}). Ability of *xylE*-bound SopB::dCas9 to prime spreading was tested by observing formation of fluorescent foci in cells also producing SopB::mVenus, a fusion protein known to act normally in complex assembly and plasmid partition \[[@pone.0226472.ref053]\]. To prevent saturation of the incipient partition complex by SopB::dCas9, its production was kept to a minimal level by allowing transcription from po*tetA* only at the basal, uninduced level, while strongly inducing production of SopB::mVenus. Compact foci of normal number and distribution appeared in *xylE*::*sopC* cells ([Fig 2A](#pone.0226472.g002){ref-type="fig"}); this was due to direct binding of SopB::mVenus *to sopC*, unmediated by the dCas9 fusion, since the foci also formed when the guide RNA carried a random sequence ([Fig 2C](#pone.0226472.g002){ref-type="fig"}). Cells without *sopC* expressing the same sgRNA and fusion genes showed no foci, only evenly distributed fluorescence ([Fig 2B and 2D](#pone.0226472.g002){ref-type="fig"}).

![Test of SopB spreading from dCas9-DNA complexes.\
Cells of strain DLT1215 and its *xylE*Ω*sopC* derivative, DLT2074, carrying the plasmids that enable SopB visualization and SopB::dCas9 binding (upper left) were applied to buffered agarose-coated slides after at least 10 generations of exponential growth in MGC medium supplemented with and 30μM IPTG; arrow width next to each plasmid indicates the relative level of RNA produced from each. Each column of images shows cells grown with the combination of dCas9 or SopB target sequence, sgRNA, SopB::dCas9 and SopB::mVenus fusion directly above.](pone.0226472.g002){#pone.0226472.g002}

It is possible that the single *xylE* binding site used does not form a core complex sufficiently robust to trigger spreading, even though a single SopB binding site does so ([S3 Fig](#pone.0226472.s003){ref-type="supplementary-material"}). So we redid the experiment with a tandem-repeat binding sequence that resembles the natural *sopC* centromere, using a guide RNA sequence corresponding to eight of the ten functional 43bp repeats that make up *sopC* \[[@pone.0226472.ref056]\]. The R219A mutant derivative of SopB was used in the fusion proteins to prevent specific binding to *sopC* while still allowing the non-specific DNA binding needed for spreading \[[@pone.0226472.ref012]\]. [Fig 2E and 2F](#pone.0226472.g002){ref-type="fig"} shows that this modification did not enable focus formation either.

S.cerevisiae URA3 {#sec024}
-----------------

Several ParB proteins, when fused to fluorescent peptides, form visible complexes in yeast strains engineered to harbour small arrays of their *parS* binding sites \[[@pone.0226472.ref003]\]. We examined the ability of such fusion proteins to form foci in the absence of their cognate *parS* sites when specific binding was provided by TALE proteins \[[@pone.0226472.ref057]\]. [Fig 3](#pone.0226472.g003){ref-type="fig"} shows the results of a representative experiment, employing an experimental format similar to that of [Fig 2](#pone.0226472.g002){ref-type="fig"}. Yeast cells transformed with a plasmid from which the ParB fusion protein Or3::mCherry is produced formed one distinct focus in each nucleus, as expected for cells in G1, provided they have an integrated copy of Or3\'s cognate centromere site, Anch3 ([Fig 3A](#pone.0226472.g003){ref-type="fig"}). No foci were seen in cells of the parental strain, which lacks this site ([Fig 3B and 3C](#pone.0226472.g003){ref-type="fig"}). When Or3::mCherry was coproduced with a fusion of Or3 to a Tale peptide known to bind specifically to the 5\' end of the *URA3* gene (Or3::Tale.U3L), it still formed foci in the Anch3 strain ([Fig 3D](#pone.0226472.g003){ref-type="fig"}) but also still failed to in cells without Anch3, whether or not they contained the Tale.U3L binding site ([Fig 3E and 3F](#pone.0226472.g003){ref-type="fig"}).

![Test of spreading by ParB specifically bound via fusion to Tale proteins in yeast.\
Or3::mCherry fusion protein production from pSA312 in: **A.** strain ySA27, with Anch3 inserted, **B.** ySA46, with no insertion, **C.** W303, with a deletion in URA3 removing the specific Tal.U3L binding site (blue strip). Or3::mCherry production together with Or3::tal.U3L from pSA316 in strains ySA27 (**D**), ySA46 (**E**) and W303 (**F**). Fusion protein elements are or3 (blue), mCherry (red), tale RVDs (yellow) and backbone (grey).](pone.0226472.g003){#pone.0226472.g003}

This outcome, no foci at all, or the other, formation of aggregates rather than *bona fide* foci, was the result of all variations tried: several different ParBs, use of tripartite fusions (ParB::FP::Tale), inverting the gene order of fusions, replacing ParBs by their Nter domains, use of stronger and weaker promoters, targeting different specific sites, use of dCas9 fusions. This was in spite of confirmation that the full-sized fusion proteins were present and constituted the bulk of the plentiful fluorescence in the nuclei ([S2B Fig](#pone.0226472.s002){ref-type="supplementary-material"}).

Our inability to see fluorescent foci representing higher-order partition complexes with either the bacterial or the yeast test systems is most simply explained as the requirement for *parS* binding of at least some of its cognate ParB molecules to enable spreading. If so, this requirement leads to the question of whether all ParB dimers must contact their *parS* for this to happen, or whether much of the postulated conformation change can be effected at the protein level.

Spreading of hybrid SopB proteins {#sec025}
---------------------------------

It should be possible to distinguish ParB-*parS* binding from ParB dimer-dimer interaction as the event that enables spreading by using hybrid proteins with centromere-binding and N-terminal domains of distinct specificities. A minimal complex seeded with limiting amounts of one ParB (the binding protein) might be expanded to a large complex upon provision of a second, hybrid ParB (the signalling protein) that shares the N-terminal domain but does not bind to the same *parS*: expansion of the complex could be observed by tagging the second ParB with a fluorescent peptide, and would indicate that direct binding to *parS* is not needed for spreading. The experimental set-up is similar to that of [Fig 2](#pone.0226472.g002){ref-type="fig"}, but here the initiating complex is natural and known to trigger spreading, and no bulky, potentially interfering foreign protein is involved.

The closely-related Sop partition systems of plasmid F and prophage-plasmid N15 appeared suitable for applying this approach. Bacteriophage N15 has sequence, structural and physiological similarities to lambdoid phages \[[@pone.0226472.ref058]\], but unlike the integrated λ prophage, N15 prophage is a linear, low copy number plasmid whose stable inheritance requires active partition. The SopB proteins of F and N15 are very similar, at 49% amino acid identity; SopB of F functions only with its cognate binding site (10 tandem copies in the F centromere, *sopC* \[[@pone.0226472.ref056]\]), not with those of N15 (IR1-4; \[[@pone.0226472.ref059]\]) \[[@pone.0226472.ref009]\]; and many N15:F hybrid proteins are functional, interacting with their SopA and centromere partners with the expected specificity \[[@pone.0226472.ref009]\]. One of these SopB proteins, SopB^N15/F^ (termed hybrid 10 by Ravin *et al*., \[[@pone.0226472.ref009]\]), comprises the N-terminal domain of N15 SopB and the DNA-binding and dimerization domains of F SopB ([Fig 4](#pone.0226472.g004){ref-type="fig"}, top left). It should be able to interact via its N-terminal domain with N15 SopB bound to IR centromere sites, but be unable to bind to these sites itself. The distribution of fluorescent SopB^N15/F^ protein confirms this specificity: discrete foci are seen in cells with *sopC* integrated as part of a prophage at attλ ([Fig 4A](#pone.0226472.g004){ref-type="fig"}), whereas in cells with an analogous N15 centromere-site array (4xIR), in which N15 SopB forms normal foci ([Fig 4C](#pone.0226472.g004){ref-type="fig"}), SopB^N15/F^::megfp fluorescence diffuses evenly throughout the cell ([Fig 4B](#pone.0226472.g004){ref-type="fig"}). The SopB^N15/F^::megfp fusion is thus sufficiently specific to serve as a signalling protein.

![Test of SopB spreading in the absence of a cognate centromere.\
Cells of strains D195 (*sopC*) / pNR195 & pNR129, D183 (*4xIR*) / pNR195 & pNR129, D183 pNR197 & pZS21, and D183 / pNR189 & pNR129 grown exponentially in MGlyC with inducers for at least 10 generations, then viewed by fluorescence microscopy. Specificity of SopB^N15/F^ binding shown by production at levels optimal (1nM aTc) or above (3nM) for visualization of complexes with **A.** sopC. **B.** 4xIR. **C.** Determination of minimal levels of arabinose-induced N15 SopB production needed to visualize complexes with 4xIR. **D**. Distribution of SopB^N15/F^ in the presence of specific N15 SopB-centromere complexes: minimal specific complexes formed at 0.1 and 0.3 μM arabinose, as shown in fluorescent form in C, are tested for initiation of fluorescent complexes containing SopB^N15/F^ produced at 1 and 3 nM anhydrotetracycline. Bar shows 1 μm.](pone.0226472.g004){#pone.0226472.g004}

To ensure that the binding proteins did not saturate spreading capacity, we assayed SopB-mediated silencing to estimate appropriate production levels. The prophage vector of the 4xIR array also carries a weak cryptic promoter, about 50bp further downstream, from which *lacZ* is transcribed, providing a sensitive measure of expansion of the partition complex in response to induced SopB^N15^ synthesis. Silencing by the SopB^N15^ protein and its mEgfp fusion derivative respond similarly to arabinose-mediated induction ([S4A Fig](#pone.0226472.s004){ref-type="supplementary-material"}), becoming discernible between 0.1 and 0.3 μM arabinose and strong above 0.6μM. This result is mirrored by focus formation, monitored in parallel ([Fig 4C](#pone.0226472.g004){ref-type="fig"})---SopB^N15^::megfp foci are scarcely seen at 0.1μM, present in most cells and discrete, though small, at 0.3μM, and of normal number and intensity at 1μM. Western blot analysis of SopB concentrations was consistent with these data ([S2C Fig](#pone.0226472.s002){ref-type="supplementary-material"}).

Accordingly, we tested whether foci initiated by wt SopB^N15^ produced at 0.1 and 0.3μM arabinose could be expanded to visible size by spreading of SopB^N15/F^::megfp produced at 1nM aTc, the optimal concentration for discrete focus formation on *sopC* ([Fig 4A](#pone.0226472.g004){ref-type="fig"}), and at 3nM aTc, for a moderate over-production ([Fig 4B](#pone.0226472.g004){ref-type="fig"}) to allow for the possibility that spreading in this heterologous system is less efficient. The results ([Fig 4D](#pone.0226472.g004){ref-type="fig"}) showed no focus formation with any combination of SopB^N15^ and SopB^N15/F^::megfp concentrations.

A variant of this approach, instigation of spreading of a ParB protein unable to bind specifically to an available centromere, is to use a mutant of a natural protein that lacks centromere-specific binding activity but is still capable of the non-specific DNA binding needed for spreading. The R219A derivative of SopB used in the experiment of [Fig 2](#pone.0226472.g002){ref-type="fig"} is such a mutant. We essentially repeated this experiment using SopB^F^ without the large peptides to which it had been fused to enable specific binding ([Fig 5](#pone.0226472.g005){ref-type="fig"}). After determining the inducer concentrations suitable for producing low levels of SopB (0.1μM arabinose) and SopB^F.R219A^::megfp (1nM aTc), using silencing assays ([S4B and S4C Fig](#pone.0226472.s004){ref-type="supplementary-material"}; [Fig 5A](#pone.0226472.g005){ref-type="fig"}), we examined the ability of the former to initiate focus formation by the latter. No foci were seen.

![Test of spreading by SopB unable to bind specifically to its centromere.\
Cells of strain D195 carrying pDAG525 & pGB2, pNR198 & pGB2, and pNR198 & pDAG607 were grown and viewed as in [Fig 4](#pone.0226472.g004){ref-type="fig"}. Focus formation at different levels of **A.** wt SopB, **B.** R219A mutant SopB, **C.** wt and mutant SopBs. Bar shows 1 μm.](pone.0226472.g005){#pone.0226472.g005}

These results provide no support for the proposal that interaction of SopB N-terminal domains alone can generate the spreading needed to assemble a functional partition complex.

Discussion {#sec026}
==========

In interpreting the results of our attempts to prime complex expansion from non-centromere DNA sites as the dependence of ParB protein spreading on cognate centromere binding, we recognise two kinds of restriction. One is that this inference is based on the absence of focus formation rather than on a positive demonstration: we cannot rule out the possibility that use of other ParB proteins or alternative experimental approaches might reveal centromere-independent spreading.

The other is imposed by difficulties with the experimental material used here. Although Tale fusion protein binding appeared durable enough to enable ParB accumulation ([S3A Fig](#pone.0226472.s003){ref-type="supplementary-material"}, line 3), dCas9 fusions might have been too fleeting to trigger nucleation despite the effectiveness of the equivalent wt fusion. In addition, the possibility that the bulky Cas9 and Tale peptides to which ParBs were fused prevented acquisition of spreading competence seemed strong for several constructions ([S3A Fig](#pone.0226472.s003){ref-type="supplementary-material"}). It was therefore important to test centromere-independent spreading without them. The use of the hybrid SopB and the SopB mutant lacking specific binding activity served this purpose. That these proteins also failed to spread when primed by core complexes whose SopB proteins shared their N-terminal domains reinforces the original interpretation. It is still possible that the R219A mutant residue or the F component of the N15/F hybrid might interfere with the conformational transitions proposed to allow Nter domain interactions. This objection could in principle be met by modifying the hybrid SopB experiment to include the missing centromere, *sopC*, and observing whether this enabled focus formation by the SopB^N15/F^::megfp protein. However, the relaxed specificity of the N15 protein that enables it to bind functionally not only to its own centromere but also to that of F would complicate interpretation and prevent drawing a more definite conclusion.

If we accept, provisionally, that centromeres promote SopB spreading by specific activation rather than by simply focussing accretion of further dimers, we can examine the validity of the alternative bases of ParB activation summarized in [Fig 1](#pone.0226472.g001){ref-type="fig"}. ParB activation mechanisms based on spontaneous conversion or ParB-ParB interaction alone (options A) would be essentially eliminated. Option Aii could still contribute as a part of mechanism Bi, in which the centromere indirectly sequesters most of the diffusible ParB in a single conformer population through selective attraction of spontaneously arising active dimers. The intrinsically disordered nature of ParB Nter domains implies that they exist as a number of metastable, interchangeable conformers of which only one or a minority can spread, as underlined by the recent study of Hyde *et al*. \[[@pone.0226472.ref038]\], lending plausibility to mechanism Bi. However, if this proposal held, the SopB^N15/F^ protein should assemble visible complexes with bound N15 SopB as readily as it does in the presence of its own centromere ([Fig 4A](#pone.0226472.g004){ref-type="fig"}), which it clearly did not ([Fig 4D](#pone.0226472.g004){ref-type="fig"}). The same objection can be raised to mechanism Bii, in which a dimer activated by centromere binding and residing there interacts with nascent dimers to induce their corresponding activation. This process, if applicable, also should have worked in the case of the N15/F protein. Notably, while mechanisms Bi and Bii both involve the centromere, the central selection or activation event occurs at the ParB protein interaction level.

Only mechanism Biii, successive and hence frequent binding and release of ParB dimers, depends solely on direct activation of ParB by the centromere, and it alone of those proposed appears to be consistent with our results. It does, however, raise the question of its compatibility with the demonstrated properties of ParB proteins, exemplified by SopB. The cohesiveness of the partition complex implies that the large majority of the cell\'s SopB dimers (\~95%, \[[@pone.0226472.ref029]\]) are activated for spreading. Data from surface plasmon resonance and *in vivo* footprinting analyses \[[@pone.0226472.ref035],[@pone.0226472.ref060]\] indicate a lengthy residence time, well in excess of a turnover time of about one minute per dimer per binding site, which we calculate (from 850 dimers in an average cell growing at two generations per hour \[[@pone.0226472.ref060]\]) would be needed to generate this activated majority, and of the 50-second half-life of Anchor3 complexes measured in human cells \[[@pone.0226472.ref004]\]. To reconcile our *in vivo* observations with the SPR and footprinting data it appeared necessary to posit a cellular element needed for rapid release of activated dimers that is absent from the *in vitro* assays. And indeed, two groups have very recently identified such an element---cytidine triphosphate (CTP; \[[@pone.0226472.ref036],[@pone.0226472.ref037]\]). These authors discerned conserved motifs in the Nter region of several ParBs, including SopB, that enable binding of CTP. The binding was strongly stimulated by centromere DNA. In the case of the *B*.*subtilis* protein, binding to *parS* and to CTP induced interaction between Nter domains to form, as the major product, a dimer ring. Stimulation of ring formation by *parS* at sub-stoichiometric levels suggested that the rings vacate their binding site rapidly to slide along adjacent DNA, i.e. to spread; the process is schematized in [Fig 6B](#pone.0226472.g006){ref-type="fig"}, together with our option Biii ([Fig 6A](#pone.0226472.g006){ref-type="fig"}) to illustrate its correspondence. If future work shows CTP-SopB-*sopC* to behave in this way, the discrepancy between our focus-formation and *in vitro* binding results would disappear.

![Model of ParB Nter activation.\
**A.** Proposed mechanism Biii from [Fig 1](#pone.0226472.g001){ref-type="fig"}; alternative fates of activated ParB after dissociation from *parS* are included. Green rod---*parS*; pink sausage---ParB monomer; maroon patch---activated Nter; blue arrow---supposed conformational switch to spreading competence. **B.** Spreading activated by CTP and *parS* binding, from [Fig 4D](#pone.0226472.g004){ref-type="fig"} in Soh et al (2019). For clarity the mechanism is shown as a series of steps, CTP binding (orange patches)---*parS* binding---ring closure, recognizing that the molecular mechanism may be more complex. CTP hydrolysis is assumed to cause dissociation of ParB from DNA and to allow recycling.](pone.0226472.g006){#pone.0226472.g006}

Given that activation of spreading ability depends on direct contact with the centromere, efforts to bring about ANCHOR visualization without it would now appear futile barring technical innovation. On the other hand, it might be possible to create mutant ParBs predisposed to adopt a spreading-competent conformation independently of their centromeres. The energy barrier to such conformers may well be low; Soh *et al*. \[[@pone.0226472.ref036]\] observed CTP to stimulate some formation of *B*.*subtilis* ParB dimer rings in the absence of *parS*, presumably from a subset of suitable conformers normally promoted by *parS* binding. A search for suitable mutants is clearly a priority.

Supporting information {#sec027}
======================

###### *E*.*coli* strains, genotype and derivation.

All transductions except the first involved cotransduction with a selective gene subsequently removed by FLP-mediated excision. Superscripts denote previously published strains (see [Table 1](#pone.0226472.t001){ref-type="table"}). Lysogenization by λRS phages to integrate promoter-*lacZ* fusions has been described \[[@pone.0226472.ref040]\]. p*cry* denotes a cryptic promoter.

(PPTX)

###### 

Click here for additional data file.

###### Western blot estimation of fusion proteins.

**A.** Cells of strain DLT1215 and of derivatives carrying pDAG114 (wt mini-F; \[[@pone.0226472.ref059]\]), pCAT05 (*sopB*^R219A^::d*cas9*) and pCAT15 (*sopB*^+^d*cas9*), from cultures growing exponentially in MGC medium, Quantities of the R219A and wt SopB::dCas9 fusions (shaded arrowheads) relative to that of mini-F (\~ 800 dimers/cell; clear arrowheads) were, respectively, 0.37 and 0.78 (left panel), and 1.1 and 0.20 (right panel), estimated using Image Lab (Biorad). Efficiency of SopB::dCas9 fusion protein transfer varied from one experiment to another: we show the results of two Western analyses of the same samples, which used MOPS buffer (left panel; irrelevant lanes between the third and fourth have been excised) and Tris-glycine (right panel) for electrophoresis and transfer. **B.** Exponential-phase cells of yeast strain W303 and derivatives harbouring plasmids that carry *megfp*::*parB*::*tal* fusions. The ladder shows prestained protein MW standards. Arrowed bands are, from left to right, those of fusions ParB^*Ralstonia*\ sp.^::Tale^U3M^ (formula MW 159kD), ParB^*S*.*pneumoniae*^::Tale^oL1λ^ (153kD), ParB^*S*.*pneumoniae*^::Tale^U3M^ (149kD), Or3::Tale^U3M^ (157kD); the band (pVR252) is Or3::mEgfp (66kD) without a Tale. The first three fusions are produced from the pHIS3 promoter, the last two from the stronger pTEF promoter. **C.** As in A, except that instead of the SopB::dCas9 fusions, wt SopB^**N15**^ in strain D183/pNR189 and wt SopB^**F**^ in D195/pDAG607 were analyzed. Arrowhead points to SopB from mini-F. Wedges represent graded arabinose inducer concentrations---0.1, 0.3, 1.0 nM and 0.03, 0.1, 0.3 nM respectively--used in the focus formation experiment of [Fig 4](#pone.0226472.g004){ref-type="fig"}.

(PPTX)

###### 

Click here for additional data file.

###### Tests of focus formation by ParB and Tale fusion constructions in *S*.*cerevisiae*.

**A.** Examples: 1 --mEgfp::Or3 forms one focus per cell in the presence (left panel) but not in the absence (right panel) of an integrated Anch3 site; 2 --fusion of tal.U3M to mEgfp::Or3 results in addition of foci with or without the Tale target site, implying susceptibility of tripartite protein to aggregation; 3 --mEgfp::ParB::Tale.oLλ protein forms one strong focus per cell by simple, FROS-like binding in cells with a target site array (left), not in cells without (right), implying normal binding properties of tripartite protein; 4 --exchange of ParB unit in tripartite protein above results in occasional, target site-independent foci, implying functional incompatibility of the new ParB; 5 --exchange of Tale unit for tal.U3M does not result in new focus; 6 --tripartite protein produced from moderate-strength promoter frequently forms a single focus per cell (though independently of target site), but 7---when produced from a stronger promoter forms several foci both outside and inside nucleus, impying aggregation rather than partition complex assembly. **B.** Other configurations used in attempts to observe partition complex foci; none gave rise to single foci in cells carrying the Tale target sequence.

(PPTX)

###### 

Click here for additional data file.

###### Estimation of partition complex expansion using promoter silencing.

**A.** Derivatives of strain D183 (4xIR---p*cry*::*lacZ*) carrying pNR189 (*sopB*^**N15**^; clear circles) or pNR197 (*sopB*^**N15**^::*megfp*; green circles) were grown exponentially for at least 10 generations in MGlyC with various concentrations of arabinose inducer, and culture samples assayed for β-galactosidase activity. Specific activity in the absence of arabinose was 17 Miller units. **B.** Strain D195 (*sopC*---p*ldc*::*lacZ*) carrying pDAG607 (*sopB*^**F**^) and pNR198 (*sopB*^**F.R219A**^) was grown and assayed as in A. Specific activity without arabinose was 525 MU. **C:** D195 carrying pDAG525 (*sopB*^**F**^::*megfp*) was grown and assayed as in A with various concentrations of anhydrotetracycline. Specific activity without arabinose was 436 MU.

(PPTX)

###### 

Click here for additional data file.

###### Interaction of target sequences with Cas9 guide RNAs.

Strains carrying chromosomal *xylE* and *sopC* sequences on the chromosome and genes for the corresponding sgRNAs on an expression vector were transformed with plasmids from which production of the SopB::dCas9 fusion or the equivalent active Cas9 fusion protein could be induced. Viability of transformants on agar medium was scored (see [Materials & methods](#sec002){ref-type="sec"}).

(DOCX)

###### 

Click here for additional data file.
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<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. We note you have included a table to which you do not refer in the text of your manuscript. Please ensure that you refer to Table 4 in your text; if accepted, production will need this reference to link the reader to the Table.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: N/A

Reviewer \#2: N/A

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: ParB proteins have the unique ability to accumulate in high copy numbers at a defined DNA recognition sequence. They are employed to visualize selected loci on a chromosome. This labeling approach requires integration of target sequences into the genome and expression of fluorescent ParB fusion proteins. The manuscript by Audibert et al. aims to simplify locus labeling by recruiting ParB to (more) freely selectable target sequences and to improve the understanding of the underlying mechanism. To do so, the presented work targets ParB proteins to alternative DNA sequences by fusion with unrelated DNA-binding proteins (dCas9 and Talen) in order to artificially nucleate local ParB enrichment.

While most of the results presented in this manuscript are negative, they are still well-worth reporting. Overall, the conclusion is that ParB proteins cannot easily be targeted to alternative DNA sequences, likely because nucleation of local ParB enrichment is tightly linked with target sequence recognition by ParB. The findings are largely consistent with the recently reported discovery of an enzymatic activity of ParB, which appears essential for local enrichment of ParB. The study is well designed, and the experiments are executed to a high standard. The experiments involving chimeric SopB proteins are particularly elegant.

The figures already include several controls that show that the experiments are working as intended. However, two (hopefully easy) control experiments should be added to make sure that the negative results are not caused by obvious experimental problems.

A\) Can the expression levels of tagged and untagged ParB variants be quantified? Semi-quantitative Western blotting may be sufficient to show that all proteins are present in reasonable amounts.

B\) All experiments rely on the specific binding of an engineered or mutant protein (dCas9 or TALEN fusion proteins and SopB R219A mutants) to a target sequence. The efficiency of the specific binding is however not directly tested for any of the presented approaches. Cell killing by Cas9 implies target sequence recognition. However, very transient or rare binding might be sufficient for cell killing, while ParB nucleation might require more stable binding. Can the localization of these proteins be demonstrated directly by ChIP-sequencing or ChIP-qPCR?

Local enrichment requires energy input. Simple uncoupling of CTP binding/hydrolysis from target sequence recognition (as alluded to at the end of the discussion) will accordingly disrupt ParB accumulation even at heterologous sites. Successful artificial targeting should require mechanistic linkage of CTP binding/hydrolysis with the (then alternative) DNA binding of the fusion partner (dCas9 or TALEN). The statement should thus be softened.

Fig. 1 (or a final figure) should include the recently proposed DNA spreading model.

A short introduction of the N15 prophage might be helpful for the less experienced reader.

Page 15, 2nd paragraphs: Please provide a list of all conditions tested for targeting (different ParBs, tripartite fusion...). Even without full documentation, the information may be useful to some readers.

Fig. 3: The ParB foci in the yeast images are quite faint. Please provide arrowheads or enhanced contrast.

Reviewer \#2: The author attempts to observe ParB spreading by the interaction of its N-terminal domain alone, rather than ParB-ParS interactions. To test the possibility, two ParB family proteins in E.coli and yeast, SopB and Or3 were fused to non-parS DNA binding fluorescent proteins. To this end, they are used to distinguish ParB-parS binding from ParB-ParB interaction. The results provide no support for the proposal that interaction of SopB N-terminal domains alone can generate the spreading needed to assemble a functional partition complex. The author finally conclude ParB proteins need their cognate centromeres to become capable of spreading.

At current level, the hypothesis raised in this work was denied by the experiment result, and no new knowledge was created. The conclusion, parB proteins need their cognate centromeres to become capable of spreading, has been extensively approved in various species. This is not the conclusion from this work. On the other hand, the context structure, logical connection and details of the language of this manuscript need improving to reach the publish level.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0226472.r002

Author response to Decision Letter 0

28 Feb 2020

Dear Dr Rybenkov

We have considered the the reviewers\' comments and your own concerning our paper \"Role of centromere sites in activation of ParB proteins for partition complex assembly\", PONE-D-19-33138.

Before detailing our responses I should point out that the original MS included two errors :

First, the version of Fig 1 submitted is not the one that corresponds to the Fig 1 legend or to the text ; the portions Bi and Biii were exchanged. This might have contributed to difficulties in following the logic of the paper. The version resubmitted has been corrected.

Second, the description of the construction of a series of plasmids, under \"SopB::mVenus visualization\" was far from complete. This has now been corrected, see p.7.

Other points :

Addition of two new supplementary figures and renumbering to preserve the correct order.

A number of minor corrections and modifications, not worth listing but readily seen in the marked up file.

The revisions necessitated addition of three more references (numbers 48, 58 and 60 in the new MS). We have also added a fourth (number 37, Osorio-Valeriano et al) because it represents the same major advance as the Soh et al paper already cited but had not come out at the time of our original submission.

Editor\'s comments :

1 - Specifically, please include additional characterization of your system to substantiate your claim that the failure of chimeric ParB to produce foci was indeed due to its inability to bind ParS and not due to other uninteresting problems with construction of chimeric proteins.

Reply: By \"inability to bind parS\" we presume you mean \"inability to spread in the absence of parS\", since this is our main conclusion. We agree that difficulties in production and behaviour of the chimeric proteins could limit the certainty of this conclusion. We have added Western blot data (Fig S2), as also suggested by Reviewer 1, to demonstrate normal levels of chimeric protein production, and a sentence to point this out (top p.16). Although in several cases (Figs 4C, 5A, S3A, \...) the chimeric proteins are still capable of binding parS, whereas in others we cannot tell whether they do or not owing to apparent abnormal behaviour (your \"uninteresting problems\" presumably) of the large chimeras. This was acknowledged in the original MS on p.15 following Fig. 3 legend \"\... formation of aggregates rather than bona fide foci \... \" and is evident in some of the examples we now provide in Fig S3. We have also underlined this phenomenon, and thus softened our conclusion, with a modified sentence (the third) of the Discussion. In fact it is exactly these limits to our conclusions of the large protein fusion experiments that lead to and justify the hybrid SopB protein experiments in which centromere binding is demonstrably not a problem and which buttress our conclusion that centromere binding is needed for focus formation.

2 - Reviewer 1 suggested a number of important controls to this end. I would also recommend a positive control, when you join the N- and C-terminal domains of ParB via the same linker that you use in other chimera and observe ParS-dependent formation of the foci.

Reply: It is not clear what new constructions are being suggested. Our general experience with joining ParB proteins to Gfp-type peptides, Nter or Cter (refs 3-5 in the MS), is that focus formation is achieved with a wide variety of linker peptides. If the order of the Nter and Cter domains of the N15-F hybrid is in question, we know (but saw no need to say) that only the hybrid used in the paper is functional, and that the equivalent F-N15 hybrid is not. If the ParB::Cas9 and ParB::Tale fusions are the point, we made no systematic attempt to test variations of linker peptide sequence or length, particularly as Tale::ParB fusions proved far more difficult to make and maintain (none appear in our Fig S3 summary) than ParB::Tale fusions, regardless of linker sequence.

3 - There is also a logical gap between your observations and the conclusion as pointed out by the Reviewer 2. It is really impossible to draw such a strong conclusion as you propose from a negative result.

Reply: We do not agree that there is a logical gap; Reviewer 2 certainly does not explain it (see comment below). We propose certain possibilities (Fig 1), test them in the experiments subsequently described, and find that only one of the possibilities is not ruled out by the results. We do not claim that this is a strong conclusion, rather that it is the only one left standing, as must be the case in the absence of a positive demonstration. The very recent provision of such a demonstration (Soh et al, Osorio et al) reinforces our conclusion but we do not pretend that this alters its essentially provisional nature.

4 - Please reword the title of your manuscript to better reflect your observations and the revise the text of the manuscript accordingly.

Reply: The title is entirely neutral. It does not say in advance what we conclude the role of centromere sites to be, or even that there necessarily is one. If one wishes to look behind its literal meaning, the title implies that centromere sites have already been proposed to have a role in ParB activation, as Reviewer 2 points out, and this study is aimed at defining that role. We do not understand why Reviewer 2 or you would object to this.

5 - 2. We note you have included a table to which you do not refer in the text of your manuscript. Please ensure that you refer to Table 4 in your text; if accepted, production will need this reference to link the reader to the Table.

Reply: We have now included reference to Table 4, under \"Plasmid constructions\" on p.6.

Reviewer \#1:

The figures already include several controls that show that the experiments are working as intended. However, two (hopefully easy) control experiments should be added to make sure that the negative results are not caused by obvious experimental problems.

A\) Can the expression levels of tagged and untagged ParB variants be quantified? Semi-quantitative Western blotting may be sufficient to show that all proteins are present in reasonable amounts.

We have included Western blot data as Fig. S2. They show that for the three experimental situations examined the amounts of full-size ParB fusion protein are at least at the levels at which the corresponding wild type ParB proteins would form partition complexes. In the case of the SopB fusion proteins this conclusion is reached by comparison with wt SopB. In the case of the Gfp::ParB::Tale fusions it is relative to visible fluorescence levels; Fig S2B shows that the full-sized fusions are the only significant anti-Gfp species present.

B\) All experiments rely on the specific binding of an engineered or mutant protein (dCas9 or TALEN fusion proteins and SopB R219A mutants) to a target sequence. The efficiency of the specific binding is however not directly tested for any of the presented approaches. Cell killing by Cas9 implies target sequence recognition. However, very transient or rare binding might be sufficient for cell killing, while ParB nucleation might require more stable binding. Can the localization of these proteins be demonstrated directly by ChIP-sequencing or ChIP-qPCR?

In vivo binding of dCas9 is generally rather stable (occupancy \>30 mins E.coli, Jones et al Science 357, 1420-1424; \>3hrs eucaryotes, Ma et al J. Cell Biol. 214, 529-537), though it is possible that at the sites used transient binding of a dCas9-parB chimera is insufficient to trigger nucleation. We have added a sentence to the start of the Discussion to cover this possibility. But whether durable or transient, binding did not enable nucleation, which was the aim of creating the chimeric proteins in the first place.

In any case ChiP is not a method of choice for measuring efficiency of binding of a single protein. It can report the presence of proteins at a given DNA locus above background, as in its successful use to demonstrate ParB::GFP spreading in yeast (Saad) and SopB::mVenus in bacteria (Sanchez). Without amplification by spreading, variation in antibody specificity and PCR efficiency makes detection of even tight binding of a single molecule unreliable. Restriction site protection would be a possibility but given the unlikelihood of brief occupancy being the problem we did not consider the investment worthwhile.

Local enrichment requires energy input. Simple uncoupling of CTP binding/hydrolysis from target sequence recognition (as alluded to at the end of the discussion) will accordingly disrupt ParB accumulation even at heterologous sites. Successful artificial targeting should require mechanistic linkage of CTP binding/hydrolysis with the (then alternative) DNA binding of the fusion partner (dCas9 or TALEN). The statement should thus be softened.

The reviewer appears to propose something other than what we are suggesting at the end of the discussion. It is hard to see how the alternative binding partner could be made to transmit the appropriate signal to the fused ParB. In any case it is the parB we would mutate, in the hope that the low energy barrier to CTP-induced transition already suggested by Soh et al\'s data (Fig. 3C) could be further lowered to the point where spontaneous transition to active conformer state replaces parS-mediated stimulation often enough to enable a focus to become visible at the alternative binding site.

We considered inserting this suggestion into the final figure recommended by the reviewer (see next) but given that isolation of an appropriate ParB mutant is entirely speculative we decided such an addition premature.

Fig. 1 (or a final figure) should include the recently proposed DNA spreading model.

The recent model is not fundamentally different from Biii, rather it is extended and far more concrete, so addition to Fig. 1 is not appropriate. We have followed the reviewer\'s suggestion to add a final figure, Fig. 6, that stresses the relationship between the two, hoping that this is what the reviewer had in mind. A few words added at the bottom of p.21 refer to it.

A short introduction of the N15 prophage might be helpful for the less experienced reader.

We have added a sentence at the bottom of p.16 to fill this gap.

Page 15, 2nd paragraphs: Please provide a list of all conditions tested for targeting (different ParBs, tripartite fusion...). Even without full documentation, the information may be useful to some readers.

We have added a supplementary figure (Fig. S3) in two parts, one (A) with images illustrating particular points (parS binding, Tale target binding, interference by aggregates), the other (B) as a list of constructions tried and tested.

Fig. 3: The ParB foci in the yeast images are quite faint. Please provide arrowheads or enhanced contrast.

The problem here was in the conversion to .pdf images. The final on-line version should be much clearer.

Reviewer \#2:

At current level, the hypothesis raised in this work was denied by the experiment result, and no new knowledge was created.

We concede, obviously, that the result was negative in the sense that no evidence was obtained for purely ParB-ParB interaction as a basis for spreading, but this is not the same as \"no new knowledge\". The essential message is \"if you are thinking about trying centromere-independent spreading, think again, it has already been tried.\"

The conclusion, parB proteins need their cognate centromeres to become capable of spreading, has been extensively approved in various species.

There is a distinction to be made here, as we explain in the Introduction (bottom, p.3) : does the need for parS in spreading consist of activating ParB to enable it, or of providing a focal point to concentrate ParB molecules which are activated by other means ? No previous study has explicitly attempted to discriminate between these two options. Several authors have suggested direct parS-mediated activation but this was opened to doubt by other observations (Surtees & Funnell; Hyde et al), as detailed in the Introduction. The reviewer goes with the common assumption but this is not the same as a demonstration. In fact it is only the very recent report by Soh et al that puts the issue beyond reasonable doubt. Our conclusion is consistent with it.

This is not the conclusion from this work.

If we understand the reviewer, this is exactly the conclusion of this work. It is just that we have also sought to examine other possible mechanisms.

On the other hand, the context structure, logical connection and details of the language of this manuscript need improving to reach the publish level.

The reviewer does not explain what problems he sees with \"the context structure\" and \"logical connection\", so there seems nothing to reply to. Likewise, what the reviewer means by improvement in \"the language of this manuscript\" is not explained.
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10 Apr 2020

PONE-D-19-33138R1

Role of centromere sites in activation of ParB proteins for partition complex assembly

PLOS ONE

Dear Lane,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Specifically, I ask you again to re-evaluate your conclusions, which at times appear to reach further than warranted by the data. This is a classic case of when a failure to prove a phenomenon does not prove its absence. I agree with the reviewer that your findings carry a constructive message. However, by overinterpreting them, you negate their impact. Please note that one of PLOS ONE publication criteria states: \"Conclusions are presented in an appropriate fashion and are supported by the data\". In my view, this means that conclusions must be clearly separated from inferences. 

Please also note other reveiewer\'s suggestions, which would undoubtfully improve the quality of your manuscript.

We would appreciate receiving your revised manuscript by May 25 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Valentin V Rybenkov

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: N/A

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors have made several modifications to the manuscript text and added control experiments in response to the reviewers' and editor's comments. They have seriously considered the comments and have made appropriate changes or alternatively provided explanations in the written response to the comments.

While the outcomes remain negative, the manuscript with its well-executed experiments will be a valuable addition to the literature, at the least instructing other researchers when attempting similar experiments in the future. Altogether, this reviewer recommends publication of the work in its current form. The authors may however consider the points given below prior to publication.

Minor points:

Following the comments from the other reviewer and the editor, the title of the manuscript could be slightly toned down to 'Addressing the role of centromeric sites in activation of ParB proteins for partition complex assembly'.

Throughout the manuscript the involvement of ParB oligomerization in ParB spreading is implicated. However, the conclusions of this work are largely independent thereof. Thus, the authors may want to consider making their work stand regardless of ParB oligomerization by eliminating such statements.

The figure legends are rather tough to read, mainly due to the listing of many genotypes. Information on genotypes could be removed from the legends altogether. The information is largely provided in the figure panels. Only strain names and plasmid names could be included in the figure legends or alternatively the use of plasmids and strains including genotypes for each figure could be listed in a separate table.

The figure legend to Figure S4 is particularly long. Please consider moving information on the Western blot protocol to the methods section.

Panel designators are not consistently noted throughout the figure legends. A : in Figure 4. A- and (A) in Figure 3. A -- in Figure 1. Please revise.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0226472.r004

Author response to Decision Letter 1

14 Apr 2020

Editor:

Specifically, I ask you again to re-evaluate your conclusions, which at times appear to reach further than warranted by the data. This is a classic case of when a failure to prove a phenomenon does not prove its absence. I agree with the reviewer that your findings carry a constructive message. However, by overinterpreting them, you negate their impact. Please note that one of PLOS ONE publication criteria states: \"Conclusions are presented in an appropriate fashion and are supported by the data\". In my view, this means that conclusions must be clearly separated from inferences.

Reply: We can only agree with the principle at issue here, though apparently you consider our attempts to deal with it in our first revision (between \[ \] below) inadequate. It would have been helpful if you could have provided a clearer indication of what you mean by \"overinterpretation\", using one or two specific examples from the text for instance. We can only suppose that you see overinterpretation in either or both of two ways : (i) any attempt to discuss the results beyond the simple observation of lack of focus formation by hybrid ParB proteins is unjustified ; (ii) we have been too assertive in summary or linking sentences -- \"concluding\" rather than \"inferring\", for example.

If your objection is the former, we would reply as follows. The major conclusion -- that ParB proteins do not spread in the absence of their centromeres -- is clearly provisional, being based in this paper only on the proteins tested and our experimental approach (one can hardly be expected to test every conceivable configuration). It does however correspond to the general assumption in the field (as seen by the attitude of reviewer 2). But once it is provisionally accepted the issue becomes what the centromere is needed for, which is why we discuss (initially in the 2nd, now the 3rd paragraph of the Discussion) the options outlined in Fig 1 and how our results bear on them, leading ineluctably to centromere activation of ParB spreading. If this is not suitable for discussion then not only does the Discussion lose most of its interest but we would have fallen far short of \"Addressing\" (as the reviewer recommends we modify the title) the topic. It would also render superfluous both the fuller perspective provided by Fig 1and the Fig 6 recommended by the reviewer.

If your objection is our manner of expression then you may have a point : readers might well get the impression of stronger finality in our statements than we intended to convey. On this assumption, we have modified the text at various points, including the Abstract, as shown in the marked up copy. In particular, we have modified the start of the Discussion to squarely explain the limits of our interpretation, and on p.20 emphasized the provisional nature of the deduced centromere role.

\[1 - Specifically, please include additional characterization of your system to substantiate your claim that the failure of chimeric ParB to produce foci was indeed due to its inability to bind ParS and not due to other uninteresting problems with construction of chimeric proteins.

Reply: By \"inability to bind parS\" we presume you mean \"inability to spread in the absence of parS\", since this is our main conclusion. We agree that difficulties in production and behaviour of the chimeric proteins could limit the certainty of this conclusion. We have added Western blot data (Fig S2), as also suggested by Reviewer 1, to demonstrate normal levels of chimeric protein production, and a sentence to point this out (top p.16). Although in several cases (Figs 4C, 5A, S3A, \...) the chimeric proteins are still capable of binding parS, whereas in others we cannot tell whether they do or not owing to apparent abnormal behaviour (your \"uninteresting problems\" presumably) of the large chimeras. This was acknowledged in the original MS on p.15 following Fig. 3 legend \"\... formation of aggregates rather than bona fide foci \... \" and is evident in some of the examples we now provide in Fig S3. We have also underlined this phenomenon, and thus softened our conclusion, with a modified sentence (the third) of the Discussion. In fact it is exactly these limits to our conclusions of the large protein fusion experiments that lead to and justify the hybrid SopB protein experiments in which centromere binding is demonstrably not a problem and which buttress our conclusion that centromere binding is needed for focus formation.\]

Reviewer \#1:

The authors have made several modifications to the manuscript text and added control experiments in response to the reviewers' and editor's comments. They have seriously considered the comments and have made appropriate changes or alternatively provided explanations in the written response to the comments.

While the outcomes remain negative, the manuscript with its well-executed experiments will be a valuable addition to the literature, at the least instructing other researchers when attempting similar experiments in the future. Altogether, this reviewer recommends publication of the work in its current form. The authors may however consider the points given below prior to publication.

Minor points:

Following the comments from the other reviewer and the editor, the title of the manuscript could be slightly toned down to 'Addressing the role of centromeric sites in activation of ParB proteins for partition complex assembly'.

Reply: We have adopted the title suggested.

Throughout the manuscript the involvement of ParB oligomerization in ParB spreading is implicated. However, the conclusions of this work are largely independent thereof. Thus, the authors may want to consider making their work stand regardless of ParB oligomerization by eliminating such statements.

Reply: Oligomerization via N-terminal domains of ParB dimers has been a regular if seldom demonstrated part of ParB research for 20 years, so we think it is appropriate to refer to it in the Introduction. But as the the reviewer points out, our results do not bear directly on oligomerization itself . And the recent model of Soh et al scarcely involves it. So from Results on we have referred simply to \"N-terminal domain\".

The figure legends are rather tough to read, mainly due to the listing of many genotypes. Information on genotypes could be removed from the legends altogether. The information is largely provided in the figure panels. Only strain names and plasmid names could be included in the figure legends or alternatively the use of plasmids and strains including genotypes for each figure could be listed in a separate table.

Reply: We have removed plasmid genotypes from the legends to Figs 2, 4 and 5, leaving only strain and plasmid names.

The figure legend to Figure S4 is particularly long. Please consider moving information on the Western blot protocol to the methods section.

Reply: The reviewer means Fig S2. As suggested, the purely protocol portions have been transposed to a new Western blotting section in Materials & Methods.

Panel designators are not consistently noted throughout the figure legends. A : in Figure 4. A- and (A) in Figure 3. A -- in Figure 1. Please revise.

Reply: Designations have been corrected for all legends, including those for Supplementary figures to the format A. .
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Dear Dr. Lane,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Valentin V Rybenkov

Academic Editor

PLOS ONE
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Dear Dr. Lane:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Valentin V Rybenkov

Academic Editor

PLOS ONE
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